4-Amino-7-[(4-fluorophenyl)methyl]pyrrolo[2,3-d]pyrimidine-5-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-Amino-7-[(4-fluorophenyl)methyl]pyrrolo[2,3-d]pyrimidine-5-carboxamide
• 化学式: C₁₄H₁₂FN₅O
• 分子量: 285.28
• InChiKey: CBSWHDVKPFBWQG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  99.8
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] PYRROLO[2,3-d]PYRIMIDINES AS ANTIVIRAL AGENTS<br/>[FR] PYRROLO[2,3-d]PYRIMIDINES UTILES EN TANT QU'AGENTS ANTIVIRAUX
  申请人：UNIV MICHIGAN

  公开号：WO2000042043A1

  公开（公告）日：2000-07-20

  This invention relates to a novel class of 4,5,6,7-substituted non-nucleoside, non-phosphorylatable pyrrolo[2,3-d]pyrimidines which exhibit both significantly lower levels of cytotoxicity and superior antiviral activity than known nucleoside, non-nucleoside, and non-nucleoside, non-phosphorylatable pyrrolo[2,3-d]pyrimidine derivatives, particularly against human DNA viruses such as cytomegalovirus (HCMV), herpes simplex virus type 1 (HSV-1). These compounds are represented by formula (I) wherein: R4 is -NR¿1?R2 or oxo; R?5¿ is -CN or -CSNR¿1?R2, or -CONR1R2; R?6¿ is -H, or halo, or -NR¿1?R2; wherein R1 and R2 are independently -H or an aliphatic group; and R?7¿ is of the formula R¿3?-Ar, wherein R3 is an aliphatic group and Ar is an unsubstituted aryl or an aryl independently substituted with halo, nitro, amino, or aliphatic groups; provided that when R?5¿ is a -CN or -CSHN¿2?, and R?6¿ is a -H or -NH¿2?; and Ar is a -C6H5 or a phenyl substituted with only one aliphatic group, R3 is an aliphatic group other than methyl such that -R3 is not a -CH2; and pharmaceutically acceptable salts, prodrugs and derivatives thereof.

  该发明涉及一类新型的4,5,6,7-取代的非核苷、非磷酸化的吡咯并[2,3-d]嘧啶类化合物，其表现出比已知的核苷、非核苷、非磷酸化的吡咯并[2,3-d]嘧啶衍生物更低的细胞毒性和更优越的抗病毒活性，特别是对人类DNA病毒如巨细胞病毒（HCMV）、单纯疱疹病毒1型（HSV-1）的抗病毒活性。这些化合物的化学式为（I），其中：R4为-NR1R2或氧；R5为-CN或-CSNR1R2，或CONR1R2；R6为-H，或卤素，或NR1R2；其中R1和R2独立地为-H或脂肪基；而R7为R3-Ar的结构，其中R3为脂肪基，Ar为未取代的芳基或独立取代有卤素、硝基、氨基或脂肪基的芳基；但是当R5为-CN或-CSHN2，R6为-H或NH2，且Ar为C6H5或只取代有一个脂肪基的苯基时，R3为除了甲基以外的脂肪基，-R3不为-CH2；以及其药物可接受的盐、前药和衍生物。
• US6342501B1
  申请人：——

  公开号：US6342501B1

  公开（公告）日：2002-01-29